XML 26 R13.htm IDEA: XBRL DOCUMENT
v3.26.1

Intangibles, Net and Goodwill | 6 Months Ended
--- | ---
Jun. 30, 2026
Intangible Asset, Goodwill and Other [Abstract] |
Intangibles, Net and Goodwill | 6. Intangibles, Net and Goodwill Intangibles, Net Finite-lived Intangible Assets As of June 30, 2026, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&D, the milestones paid to PARI Pharma GmbH (PARI) for the license to use the Lamira® Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the FDA and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively, the milestone paid to AstraZeneca AB (AstraZeneca) as a result of the FDA approval of BRINSUPRI in August 2025, and the milestone paid to AstraZeneca as a result of the EC approval of BRINSUPRI in November 2025. The Company began amortizing its acquired ARIKAYCE R&D and PARI milestone-related intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years, and began amortizing its AstraZeneca milestone-related intangible assets in August and November 2025 over BRINSUPRI's regulatory exclusivity period of approximately 14 years. Amortization expense is estimated to be $8.3 million per year for the years 2026 through 2029 and $7.1 million for 2030. Indefinite-lived Intangible Assets As of June 30, 2026, the Company's indefinite-lived intangible assets consisted of acquired IPR&D from the Business Acquisition. Indefinite-lived intangible assets are not amortized. A rollforward of the Company's intangible assets for the six months ended June 30, 2026 and 2025 is as follows (in thousands):
Intangible Asset |  | December 31, 2025 |  | Additions |  | Amortization |  | June 30, 2026
Acquired ARIKAYCE R&D |  | $ | 23,038 |  |  | $ | — |  |  | $ | (2,425) |  |  | $ | 20,613 |
PARI milestones |  | 962 |  |  | — |  |  | (101) |  |  | 861 |
AstraZeneca milestones |  | 44,051 |  |  | — |  |  | (1,636) |  |  | 42,415 |
Acquired IPR&D |  | 29,600 |  |  | — |  |  | — |  |  | 29,600 |
|  | $ | 97,651 |  |  | $ | — |  |  | $ | (4,162) |  |  | $ | 93,489 |
Intangible Asset |  | December 31, 2024 |  | Additions |  | Amortization |  | June 30, 2025
Acquired ARIKAYCE R&D |  | $ | 27,888 |  |  | $ | — |  |  | $ | (2,425) |  |  | $ | 25,463 |
PARI milestones |  | 1,164 |  |  | — |  |  | (101) |  |  | 1,063 |
Acquired IPR&D |  | 29,600 |  |  | — |  |  | — |  |  | 29,600 |
|  | $ | 58,652 |  |  | $ | — |  |  | $ | (2,526) |  |  | $ | 56,126 |
Goodwill The Company's goodwill balance of $136.1 million as of June 30, 2026 and December 31, 2025, resulted from the August 2021 Business Acquisition.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for intangible asset. Includes, but is not limited to, finite- and indefinite-lived intangible assets, capitalized cost for internal-use software and software to be sold, leased, or marketed. Excludes goodwill. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration